ArticleFrontiers in oncology2025
Pan-cancer analysis of integrin alpha family and prognosis validation in head and neck squamous cell carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Integrins are cell-surface receptors involved in the interaction of cells with the extracellular matrix and are essential for processes such as cell adhesion, migration, and proliferation. However, the specific mechanisms by which integrin α family (ITGA) genes contribute to tumorigenesis and progression remain to be thoroughly explored. Methods: In this study, based on The Cancer Genome Atlas, we explored the differential expression of ITGA family genes in 33 types of tumors and normal tissues. Univariate COX regression was employed to analyze its association with the survival outcomes of pan-cancer patients. Online tools were utilized to analyze genetic changes of the genes, study the relationship with immune subtypes and evaluate immune cells, and analyze the relationship with tumor mutational burden and stemness. Additionally, immunohistochemistry experiments were conducted on Head and neck squamous cell carcinoma (HNSC) tissue samples to assess the impact of ITGA3 and others on patient prognosis. Results: ITGA family genes are abnormally expressed in most tumors and are significantly associated with poor prognosis. Genetic changes in these genes are mainly amplifications, and the mutation group has a poor prognosis. The differential expression of ITGA family genes is related to increased immune-related scores and immune cells. In HNSC, the high expression of ITGA3/5/6 serves as a biomarker for poor prognosis. Conclusion: Our research results indicate that ITGA family genes can serve as valuable prognostic biomarkers and therapeutic targets for tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.